Eirion Therapeutics to Showcase Innovation at 2025 AAD Innovation Academy

Eirion Therapeutics to Present Promising Hair Loss Trial Results at Dermatology Innovation Academy

CHICAGO, IL – July 9, 2025 – Eirion Therapeutics Inc. today announced it will unveil compelling data from its first-in-human trial of ET-02, a once-daily topical treatment for androgenetic alopecia (male/female pattern baldness), at teh American Academy of Dermatology Innovation Academy meeting in Chicago, July 10-13.

The presentation, scheduled for Thursday, July 10th from 1:00 PM – 5:00 PM CST as part of the “Future of Dermatology Symposium: The New Skin Frontier: Innovation at the Intersection of Biopharma and academia,” will be delivered by Eirion’s CEO & President, Dr.Jon Edelson.Initial trial results indicate ET-02 may outperform the current leading topical treatment,minoxidil. According to the company, once-daily submission of 5% ET-02 demonstrated greater hair regrowth after just one month compared to four months of twice-daily 5% topical minoxidil treatment in separate clinical trials. Minoxidil is widely considered the “gold standard” for topical hair loss solutions.”These findings represent a possibly notable advancement in how we approach androgenetic alopecia,” said Dr. Edelson. “Millions struggle wiht hair loss, and the prospect of a more effective, convenient treatment is incredibly exciting.”

Understanding Androgenetic Alopecia & the Search for Better Treatments

Androgenetic alopecia is a common condition affecting both men and women, characterized by a gradual thinning of hair. While various treatments exist, including oral medications and surgical options, topical solutions like minoxidil remain a popular first-line defense. However, minoxidil often requires consistent, long-term use and can produce modest results.

Eirion Therapeutics is focused on developing a pipeline of next-generation prescription aesthetic dermatology products, including treatments for hair greying, wrinkles, and excessive sweating (hyperhidrosis). The company’s focus on novel small molecule treatments aims to address unmet needs in the aesthetic dermatology space.

Looking Ahead

Eirion Therapeutics, a privately held clinical-stage biopharmaceutical company, plans to continue expanding its research and development efforts to address a broader range of dermatological conditions.For more facts, visit www.eirionthera.com.

Media Contact:

Megan Driscoll
Evolvemkd
[email protected]

What specific mechanism does Eirion Therapeutics’ therapy utilize too address CLE, and how does this differ from current broad immunosuppression treatments?

Pioneering Research in Cutaneous Lupus Erythematosus to be Presented

Eirion Therapeutics is set to present its groundbreaking research at the 2025 American academy of Dermatology (AAD) Innovation Academy, a prestigious event dedicated to showcasing cutting-edge advancements in dermatology.The company will focus on its novel therapeutic approach for treating cutaneous lupus erythematosus (CLE), a chronic autoimmune skin disease. This presentation marks a important step forward in the advancement of targeted therapies for complex dermatological conditions.

Understanding Cutaneous Lupus Erythematosus & current Treatment Landscape

Cutaneous Lupus Erythematosus (CLE) encompasses a spectrum of skin manifestations, impacting patients with varying degrees of severity. Current treatment options often involve broad immunosuppression, which can lead to significant side effects. These include increased susceptibility to infection,and long-term health complications.

Subacute cutaneous Lupus Erythematosus (SCLE): Characterized by non-scarring, photosensitive skin lesions.

Chronic Cutaneous Lupus Erythematosus (CCLE): Frequently enough presents with disfiguring, scarring lesions, especially on the face, ears, and scalp.

Acute Cutaneous Lupus Erythematosus (ACLE): Typically associated with systemic lupus erythematosus and presents as a butterfly-shaped rash across the face.

The need for more targeted and effective treatments with improved safety profiles is paramount. Eirion Therapeutics’ research directly addresses this unmet need.

Eirion Therapeutics’ Innovative Approach: Targeting the Interferon Pathway

Eirion Therapeutics is developing a first-in-class, topical small molecule therapy designed to selectively inhibit the Type I Interferon (IFN) pathway. This pathway is critically implicated in the pathogenesis of CLE. By specifically targeting IFN signaling at the source of inflammation – the skin – Eirion aims to minimize systemic exposure and reduce the risk of adverse effects.

Key Features of Eirion’s Therapeutic Candidate:

Topical Formulation: Allows for direct delivery to affected skin areas, maximizing efficacy and minimizing systemic absorption.

Selective IFN Inhibition: Precisely targets the IFN pathway, avoiding broad immunosuppression.

Novel Small Molecule: Represents a new chemical entity with a unique mechanism of action.

Potential for Improved Safety: Reduced systemic exposure translates to a potentially improved safety profile compared to existing treatments.

What to Expect at the AAD Innovation Academy Presentation

Eirion Therapeutics will present pre-clinical data demonstrating the efficacy of its therapeutic candidate in relevant CLE models. The presentation will cover:

1. Mechanism of Action: A detailed explanation of how the small molecule inhibits the Type I IFN pathway.
2. In-Vitro Studies: Results showcasing the compound’s ability to suppress IFN-stimulated gene expression in CLE-affected skin cells.
3. In-Vivo Efficacy: Data from animal models demonstrating the reduction of skin inflammation and disease severity following topical application.
4. Safety Profile: preliminary safety data indicating minimal systemic absorption and favorable tolerability.

Attendees will have the prospect to engage with Eirion’s scientific team and learn more about the potential of this innovative therapy. The presentation is scheduled for [Insert Date/time] at the AAD Innovation Academy.

The Meaning of the AAD Innovation Academy

The AAD Innovation Academy serves as a crucial platform for showcasing emerging technologies and fostering collaboration within the dermatology community. Presenting at this event allows Eirion Therapeutics to:

gain Visibility: Increase awareness of its innovative approach among key opinion leaders, potential partners, and investors.

Receive Feedback: Gather valuable insights from experts in the field to refine its development strategy.

Accelerate Development: Explore potential collaborations to expedite the clinical translation of its therapeutic candidate.

* Contribute to the Field: Advance the understanding of CLE pathogenesis and the development of novel therapies.

Future Directions & Clinical Development Plans

Following the AAD presentation, Eirion Therapeutics plans to initiate Phase 1 clinical trials to evaluate the safety and tolerability of its topical therapy in healthy volunteers. Subsequent phases will assess efficacy in patients with CLE. The company is committed to advancing this promising therapeutic candidate through the clinical development process and ultimately bringing a much-needed new treatment option to patients suffering from this debilitating disease. The long-term goal is to provide a disease-modifying therapy that improves the quality of life for individuals affected by cutaneous lupus erythematosus.